IBG Beteiligungsgesellschaft Sachsen-Anhalt

InLine-Med GmbH, established in 2019 and based in Magdeburg, Germany, specializes in developing assistance devices that enhance the efficiency and accuracy of needle-based interventions for radiologists. The company offers a range of products, including navigation devices, surgical tools, needle alignment tools, and anatomical marker grids, along with navigation software that aids in visualization and intervention planning. By integrating artificial intelligence with innovative guiding tools and high-quality biopsy needles, InLine-Med addresses the challenges of accurate needle placement, which is crucial in cancer diagnosis and treatment. Their solution allows clinicians to define a needle trajectory on a computer and seamlessly translate this plan to the patient, minimizing the need for multiple punctures and reducing procedure times. The comprehensive suite of assistance tools is competitively priced, enabling clinicians to conduct safe and precise interventions without relying on complex robotic systems.

COMAN Software GmbH specializes in developing software solutions tailored for machine and plant construction. Founded in 2018 and headquartered in Gardelegen, Germany, the company offers a project management platform that enhances efficiency and transparency in construction projects. Key features include real-time data capture, easy import of project data, automated status report generation, and mobile access to project information. This software aims to optimize project planning and execution, reduce construction times, and minimize errors through centralized data management and streamlined communication. Additionally, COMAN Software provides various services, including support, training, and consulting, to assist clients in effectively utilizing their platform. The company's innovative approach enables businesses to enhance collaboration, stay on schedule, and manage projects within budget.

Lab-on-Fiber GmbH, based in Halle, Germany, specializes in the development and production of advanced medical laser probes and systems aimed at enhancing minimally invasive surgical procedures. The company offers a range of fiber delivery systems, including surgical and urology fiber probes. By providing optimized radiation profiles and real-time temperature monitoring at the probe surface, Lab-on-Fiber's technology helps surgeons reduce operating times, improve treatment outcomes, and enhance patient safety. Their innovative solutions are designed to streamline laser surgery while minimizing potential complications, positioning Lab-on-Fiber as a key player in the medical technology sector.

TESVOLT GmbH, established in 2014 and headquartered in Wittenberg, Germany, specializes in the development and manufacturing of lithium battery storage systems aimed at the commercial and industrial sectors. As a recognized leader in energy storage solutions in Germany and Europe, TESVOLT produces intelligent lithium storage systems with power capacities ranging from 10 kilowatt hours to several megawatt hours, all manufactured in a carbon-neutral gigafactory. Their products facilitate companies in reducing energy dependency and contribute to the transition toward renewable energy sources, including solar, wind, and biogas. The company has been acknowledged with various awards for its innovative approaches, driven by its co-founders Daniel Hannemann and Simon Schandert, who have extensive experience in the photovoltaic sector. TESVOLT's focus on developing economical storage solutions is complemented by its commitment to safety and quality, as evidenced by TÜV certification for its products.

Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. Wilfried Fischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany.

2tainment GmbH is a video game publisher and developer based in Magdeburg, Germany, founded in 2014. The company specializes in creating and marketing both hardware and software entertainment products on an international scale. Its portfolio includes various games such as Tech Corp, BIOTOPE – Aquarium Simulator, Air Missions: HIND, Super Street, Club Manager 2017, and Crashday. In addition to game development, 2tainment focuses on enhancing player experiences through high-quality PC, mobile, and video game accessories, including game pads, charger stations, and keyboards. The company also emphasizes virtual and augmented reality, not only creating its own content but also supporting external studios. Beyond gaming, 2tainment engages in research and development projects, aiming to improve medical treatment methods through its expertise in VR and AR technologies. This dual focus on entertainment and healthcare positions 2tainment as a versatile player in the gaming industry.

Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. Wilfried Fischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany.

Micropelt is a startup that emerged from a collaborative project between Infineon Technologies AG and the Fraunhofer Institute for Physical Measurement Techniques in Germany. The company specializes in developing thin film thermoelectric components through semiconductor manufacturing processes. Micropelt focuses on creating energy-harvesting systems that integrate micro-actuators and sensors. Its product offerings include thermoelectric cooling chips and thermoelectric generators designed for various applications, such as chip spot cooling, biomedical devices, heating, ventilation, and air conditioning systems, as well as fiber optics. These innovations aim to facilitate effective temperature management in individual rooms while contributing to CO2 reduction and enhancing user comfort. The company has secured funding from several financial institutions, enabling its growth and development within the thin-film technology sector.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

EUCODIS Bioscience GmbH is a manufacturer of enzyme solutions that cater to various industries, including biopharma, fine chemicals, and cosmetics. Established in 2007 and based in Vienna, Austria, with a subsidiary in Germany, the company produces a diverse range of enzymes such as lipases, peroxidases, and nitrile hydratases. These enzymes facilitate applications including the stereospecific resolution of chiral alcohols and acids for active pharmaceutical ingredient synthesis, the production of sensitive esters, and the selective hydrolysis of fatty acids. Additionally, EUCODIS offers services in protein and enzyme engineering, bioprocess development, and industrial manufacturing. Their products are utilized by leading companies in the chemical, pharmaceutical, food, and cosmetics sectors to enhance production efficiency and comply with environmental standards.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

metraTec GmbH is a German company that specializes in the manufacturing and supply of RFID hardware products. Based in Magdeburg and founded in 2006, metraTec offers a diverse range of products including HF and UHF readers, UHF gates, RFID readers/writers, antennas, transponders, and RFID modules. These products are utilized across various applications such as logistics, document management, access control systems, and e-ticketing. The company serves multiple industries, focusing primarily on logistics, healthcare, and security, and provides both standard and custom solutions to system integrators, OEM customers, and research institutions, particularly in Europe. In addition to RFID technology, metraTec also develops solutions for indoor localization, wireless mesh communication, and wireless power transmission, contributing to advancements in the Internet of Things. The company was previously known as metraTec RFID Solutions until its name change in 2008.